denkapparat Operations GmbH Invests $834,000 in Bristol-Myers Squibb (NYSE:BMY)

denkapparat Operations GmbH bought a new stake in Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,748 shares of the biopharmaceutical company’s stock, valued at approximately $834,000. Bristol-Myers Squibb makes up 1.2% of denkapparat Operations GmbH’s holdings, making the stock its 12th largest position.

Other large investors have also recently bought and sold shares of the company. Orion Portfolio Solutions LLC boosted its holdings in Bristol-Myers Squibb by 8.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 42,933 shares of the biopharmaceutical company’s stock worth $2,428,000 after acquiring an additional 3,436 shares during the last quarter. Premier Fund Managers Ltd boosted its stake in Bristol-Myers Squibb by 9.5% in the fourth quarter. Premier Fund Managers Ltd now owns 186,300 shares of the biopharmaceutical company’s stock valued at $10,445,000 after acquiring an additional 16,100 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Bristol-Myers Squibb by 14.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,295,890 shares of the biopharmaceutical company’s stock worth $73,296,000 after purchasing an additional 161,739 shares during the last quarter. Frazier Financial Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 91.7% in the 4th quarter. Frazier Financial Advisors LLC now owns 694 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 332 shares during the period. Finally, New Age Alpha Advisors LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $7,111,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $58.90 on Friday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a 50 day moving average of $58.47 and a two-hundred day moving average of $56.17. The stock has a market cap of $119.52 billion, a P/E ratio of -13.33, a P/E/G ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.21%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on BMY shares. Citigroup raised their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Truist Financial boosted their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday, February 7th. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Finally, Bank of America restated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.